Cousin vs. Sibling Donors in Haplo-HSCT
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorThe First Affiliated Hospital of Soochow University
About this trial
This observational study aims to emulate a hypothetical pragmatic, multicenter, non-blinded clinical trial enrolling adult patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with grafts derived from either cousin or sibiling donors.
The main research question is whether cousin donor-derived haplo-HSCT is associated with inferior clinical outcomes relative to sibling donor-derived haplo-HSCT.
Study participants consist of adult patients diagnosed with hematological malignancies who underwent cousin or sibiling haplo-HSCT between 2017 and 2024, and all eligible recipients will receive regular follow-up assessments.
Eligibility criteria
Qualifiers
Adult patients diagnosed with hematological malignancies, including acute leukemia (AL), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and non-Hodgkin lymphoma (NHL)
Receipt of first haploidentical hematopoietic stem cell transplantation between 2017 and 2024
Documented exact date of transplantation available in medical charts
Verifiable donor kinship classified as either cousin or sibiling
Disqualifiers
Prior receipt of any form of hematopoietic stem cell transplantation
An age difference of more than 18 years between the donor and recipient
Failure of successful infusion of donor-derived hematopoietic stem cells following conditioning regimen
Trial design
Treatments tested in this trial
- Not listed
Trial groups
1,000 Participants
are grouped into 2 trial groupsSponsors and collaborators
The First Affiliated Hospital of Soochow University
Lead sponsor
Ruijin Hospital
Collaborator
Nanfang Hospital, Southern Medical University
Collaborator
Zhejiang University
Collaborator
Source ClinicalTrials.gov